Pfizer Spends Big on IP Lobbying With Billions on the Line
The pharmaceutical giant spent big bucks amid key international negotiations last year to protect record earnings.
The pharmaceutical giant spent big bucks amid key international negotiations last year to protect record earnings.
A group of Republican senators sought to block U.S. support for an IP waiver for Covid-19 vaccines, a proposal that is strongly opposed by the pharmaceutical industry.